See more : Formuepleje Mix High (FPIMHI.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Tyra Biosciences, Inc. (TYRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tyra Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- EROAD Limited (ERDLF) Income Statement Analysis – Financial Results
- Shanxi Xinghuacun Fen Wine Factory Co.,Ltd. (600809.SS) Income Statement Analysis – Financial Results
- Axis Real Estate Investment Trust (5106.KL) Income Statement Analysis – Financial Results
- Kronos Advanced Technologies Inc. (KNOS) Income Statement Analysis – Financial Results
- Vmoto Limited (VMT.AX) Income Statement Analysis – Financial Results
Tyra Biosciences, Inc. (TYRA)
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 353.00K | 296.00K | 140.00K | 47.00K | 8.00K |
| Gross Profit | -353.00K | -296.00K | -140.00K | -47.00K | -8.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 62.52M | 43.01M | 20.64M | 7.20M | 1.79M |
| General & Administrative | 17.43M | 15.92M | 5.65M | 2.09M | 1.33M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.43M | 15.92M | 5.65M | 2.09M | 1.33M |
| Other Expenses | 0.00 | -50.00K | -19.00K | -23.00K | -8.00K |
| Operating Expenses | 79.95M | 58.93M | 26.29M | 9.30M | 3.12M |
| Cost & Expenses | 79.95M | 58.93M | 26.29M | 9.30M | 3.12M |
| Interest Income | 10.85M | 3.65M | 13.00K | 1.00 | 1.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 1.00K | 1.00K |
| Depreciation & Amortization | 353.00K | 296.00K | 140.00K | 47.00K | 8.00K |
| EBITDA | -79.59M | -58.63M | -26.15M | -9.25M | -3.11M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -79.95M | -58.93M | -26.29M | -9.30M | -3.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.81M | 3.60M | -6.00K | -39.00K | -943.00K |
| Income Before Tax | -69.13M | -55.33M | -26.29M | -9.34M | -4.07M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.60M | -153.00K | -22.00K | -7.00K |
| Net Income | -69.13M | -51.72M | -26.14M | -9.31M | -4.06M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.62 | -1.23 | -0.63 | -0.22 | -0.10 |
| EPS Diluted | -1.62 | -1.23 | -0.63 | -0.22 | -0.10 |
| Weighted Avg Shares Out | 42.70M | 41.88M | 41.44M | 42.54M | 42.54M |
| Weighted Avg Shares Out (Dil) | 42.70M | 41.88M | 41.44M | 42.54M | 42.54M |
Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings
CARLSBAD, Calif. , Sept. 21, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that TYRA will deliver oral...
Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference
CARLSBAD, Calif. , Sept. 12, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate at...
Tyra Biosciences: FDA ODD Designation Progresses TYRA-300
Tyra's net loss continues to improve in Q2 2023. TYRA-300 has been granted Orphan Drug Designation status by the FDA recently, continuing its progression to market. Tyra's substantial cash reserves and ongoing trials support the development of its pipeline for...
Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights
-Orphan Drug Designation granted to TYRA-300 for achondroplasia- - SURF301 Phase 1/2 oncology study remains on target; enrollment ongoing in Part B - -TYRA-200 Phase 1 study on track; first patient to be dosed in 2H 2023- - Strong cash...
Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia
CARLSBAD, Calif. , Aug. 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that the U.S. Food...
Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet
The consensus price target hints at a 52.2% upside potential for Tyra Biosciences, Inc. (TYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness...
Tyra Biosciences: Early Stage Developer Of Novel FGFR3-Selective Molecules
TYRA has the first FGFR3 inhibitor in the clinic. The company has a large market cap for an early-stage company and a good deal of cash. They do not have clinical data yet.
Tyra Biosciences to Participate in Upcoming Investor Conferences
CARLSBAD, Calif. , May 25, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in...
What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing'
Tyra Biosciences, Inc. (TYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. (TYRA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price...
Source: https://incomestatements.info
Category: Stock Reports